摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-3-(2-{[3-(pyrimidin-5-yl)pyrazin-2-yl]oxy}ethyl)-1H-pyrrolo[3,2-b]quinoline | 1603830-30-3

中文名称
——
中文别名
——
英文名称
1-methyl-3-(2-{[3-(pyrimidin-5-yl)pyrazin-2-yl]oxy}ethyl)-1H-pyrrolo[3,2-b]quinoline
英文别名
1-Methyl-3-[2-(3-pyrimidin-5-ylpyrazin-2-yl)oxyethyl]pyrrolo[3,2-b]quinoline;1-methyl-3-[2-(3-pyrimidin-5-ylpyrazin-2-yl)oxyethyl]pyrrolo[3,2-b]quinoline
1-methyl-3-(2-{[3-(pyrimidin-5-yl)pyrazin-2-yl]oxy}ethyl)-1H-pyrrolo[3,2-b]quinoline化学式
CAS
1603830-30-3
化学式
C22H18N6O
mdl
——
分子量
382.425
InChiKey
DRRKYESEMTWDAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    78.6
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I
    作者:Sanjib Das、Rajendra L. Harde、Dnyaneshwar E. Shelke、Neelima Khairatkar-Joshi、Malini Bajpai、Ratika S. Sapalya、Harshada V. Surve、Girish S. Gudi、Rambabu Pattem、Dayanidhi B. Behera、Satyawan B. Jadhav、Abraham Thomas
    DOI:10.1016/j.bmcl.2014.03.054
    日期:2014.5
    We report analogue-based rational design and synthesis of two novel series of polycyclic heteroarenes, pyrrolo[3,2-b]quinolines and pyrido[2,3-b]indoles, tethered to a biaryl system by a methyl-, ethyl-or propyl ether as PDE10A inhibitors. A number of analogues were prepared with variable chain length and evaluated for their ability to block PDE10A enzyme using a radiometric assay. Detailed SAR analyses revealed that compounds with an ethyl ether linker are superior in potency compared to compounds with methyl or propyl ether linkers. These compounds, in general, showed poor metabolic stability in rat and human liver microsomes. The metabolic profile of one of the potent compounds was studied in detail to identify metabolic liabilities of these compounds. Structural modifications were carried out that resulted in improved metabolic stability without significant loss of potency. (C) 2014 Elsevier Ltd. All rights reserved.
查看更多